Ioflupane (123I)

Source: Wikipedia, the free encyclopedia.
Ioflupane (123I)
INN: ioflupane
Clinical data
Trade namesDatscan, Striascan, Celsunax
Other namesIoflupane (FPCIT);
[I-123] N-ω-fluoropropyl- 2β-carbomethoxy- 3β-(4-iodophenyl) nortropane
AHFS/Drugs.comProfessional Drug Facts
License data
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityN/A
ExcretionKidney and fecal
Identifiers
  • methyl (1R,2S,3S,5S)- 3-(4-iodophenyl)- 8-(3-fluoropropyl)- 8-azabicyclo[3.2.1]octane- 2-carboxylate
JSmol)
  • COC(=O)[C@@H]1[C@H]2CCC(N2CCCF)C[C@@H]1C3=CC=C(C=C3)[123I]
  • InChI=1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1/i20-4
  • Key:HXWLAJVUJSVENX-HFIFKADTSA-N
 ☒NcheckY (what is this?)  (verify)

Ioflupane (123I) is the

GE Healthcare
, formerly Amersham plc.

DaTSCAN
showing normal Ioflupane (123I) uptake in the striatum.

Pharmacology

Datscan is a solution of ioflupane (123I) for injection into a living test subject.[7]

The

keV making it an appropriate radionuclide for medical imaging. The solution also contains 5% ethanol to aid solubility and is supplied sterile since it is intended for intravenous use.[7]

Ioflupane has a high binding affinity for presynaptic

dopaminergic neurons
in the striatal region. By introducing an agent that binds to the dopamine transporters a quantitative measure and spatial distribution of the transporters can be obtained.

Method of administration

The Datscan solution is supplied ready to inject with a certificate stating the calibration activity and time. The nominal injection activity is 185 MBq[7] and a scan should not be performed with less than 111 MBq.

Thyroid blocking via oral administration of 120 mg potassium iodide is recommended to minimize unnecessary excessive uptake of radioiodine.[8] This is typically given 1–4 hours before the injection.[7][9]

The most convenient way to administer the IV dose is via a peripheral intravenous cannula. The scan is carried out 3 to 6 hours post injection.[8][9]

Pharmacokinetics

Blood clearance of the radionuclide is rapid in healthy volunteers.[10] Radioactivity was 4.5% of the injected amount 5 min after injection of ioflupane (123I), falling to 2.2% at 30 min, 1.9% at 5 h, and declining to 1.3% at 24 h and 1.1% at 48 h after injection. Values were similar in both whole blood and plasma. Excretion was primarily renal.

Risks

Common side effects of ioflupane (123I) are headache, vertigo, increased appetite and formication. Less than 1% of patients experience pain at the injection site.[7]

The radiation risks are reported as low. The committed

mSv.[11] Pregnant patients should not undergo the test. It is not known if 123I-ioflupane is secreted in breast milk however it is recommended that breastfeeding be interrupted for three days after administration.[7]

See also

References

  1. ^ "Neurological therapies". Health Canada. 9 May 2018. Retrieved 13 April 2024.
  2. ^ "Datscan- ioflupane i-123 injection, solution". DailyMed. 31 March 2020. Retrieved 23 April 2021.
  3. ^ "Removal of [123I]Ioflupane From Schedule II of the Controlled Substances Act". DEA Diversion Control Division. Archived from the original on 13 May 2017. Retrieved 2016-02-09.
  4. ^ "Datscan EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 1 July 2021.
  5. ^ "Striascan EPAR". European Medicines Agency (EMA). 24 April 2019. Retrieved 1 July 2021.
  6. ^ "Celsunax EPAR". European Medicines Agency (EMA). 20 April 2021. Retrieved 1 July 2021.
  7. ^ a b c d e f g "Datscan Summary of Product Characteristics" (PDF). European Medicines Agency. GE Healthcare. 25 July 2019.
  8. ^
    PMID 19838702
    .
  9. ^ .
  10. .
  11. ^ "Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources". ARSAC. Public Health England. 13 February 2019.